Pharmacopsychiatry 2018; 51(06): 270-271
DOI: 10.1055/s-0043-122603
Letter to the Editor
© Georg Thieme Verlag KG Stuttgart · New York

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

Sara Baldelli
1   Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
,
Emilio Clementi
2   Clinical Pharmacology Unit, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Department of Biomedical and Clinical Sciences L. Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
3   E. Medea Scientific Institute, Bosisio Parini, Italy
,
Dario Cattaneo
1   Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 16. Oktober 2017
revised 26. Oktober 2017

accepted 07. November 2017

Publikationsdatum:
27. November 2017 (online)

Preview

Abstract

The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.